In this section, the regulations in the 2002 PAL amendment of drug companies are detailed. Since 1971, Japan has adopted a system for the ‘re-examination’ and ‘re-evaluation’ of marketed drugs.
ENHANCEMENT OF POST-MARKETING
SAFETY MEASURES
In
this section, the regulations in the 2002 PAL amendment of drug companies are
detailed. Since 1971, Japan has adopted a system for the ‘re-examination’ and
‘re-evaluation’ of marketed drugs. The ‘re-examination’ system involves a
reassessment of the usefulness of all new drugs after a fixed period of time (6
years for usual products, 10 years for orphan drugs) following the first
approval. Unless the results of the ‘re-examination’ indicate that the product
has no major problem, the manufacturer (currently, MAH) is no longer allowed to
market the product. On the other hand, the quality, efficacy and safety of the
approved drug may be subject to ‘re-evaluation’ based on the advancement of
medi-cal and pharmaceutical sciences. Since April 1997, the ‘re-examination’
system has been further system-ized where the basic plan of post-marketing
studies is required to be submitted at the stage of the approval of the new products.
The result of the post-marketing study has been also requested to be included
in Peri-odic Safety Update Report (PSUR) in line with the implementation of
ICH-E2C guideline (on PSUR) in April 1997. As an additional regulation,
Early-Phase Post-marketing Vigilance (EPPV) has been introduced in 2001 that is
unique to Japan. According to this regu-lation, the MAHs are required to
repeatedly explain the appropriate use of the new drug to health
profes-sionals, collect information on serious ADRs through intensive
monitoring for spontaneous reports, and keep a record of the vigilance for the
first 6 months after launch.
The
details for these regulations, including those for the EPPV, were given in the
‘Good Post-Marketing Surveillance Practice’ (GPMSP), first made as a notice in
1994 and then promulgated as a ministerial ordinance in 1997. The GPMSP covered
the regula-tions on EPPV, ADR reports and risk communica-tion as well as those
on the investigational studies conducted by the drug companies. Following the
2002 PAL amendment, in 2004 the GPMSP was divided into two ministerial
ordinances of ‘Good Vigilance Practice’ (GVP) for the regulations of the ADR
reports and risk communication, and ‘Good Postmarketing Study Practice’ (GPSP)
for the regulations of the investigational studies.
Related Topics
TH 2019 - 2024 pharmacy180.com; Developed by Therithal info.